{"id":"NCT02630706","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Monotherapy (VERTIS-ASIA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-16","primaryCompletion":"2017-12-27","completion":"2017-12-27","firstPosted":"2015-12-15","resultsPosted":"2018-12-07","lastUpdate":"2018-12-07"},"enrollment":506,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Ertugliflozin 5 mg","otherNames":["MK-8835","PF-04971729"]},{"type":"DRUG","name":"Ertugliflozin 15 mg","otherNames":["MK-8835","PF-04971729"]},{"type":"DRUG","name":"Placebo matching ertugliflozin","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]},{"type":"DRUG","name":"Glimepiride","otherNames":[]}],"arms":[{"label":"Ertugliflozin 5 mg","type":"EXPERIMENTAL"},{"label":"Ertugliflozin 15 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study to evaluate the efficacy and safety of the addition of ertugliflozin to metformin monotherapy in Asian participants with Type 2 diabetes mellitis (T2DM) who have inadequate glycemic control on metformin monotherapy. The primary hypothesis is that the mean reduction from baseline in HbA1C for 15 mg and 5 mg ertugliflozin (tested sequentially) is greater than for placebo.","primaryOutcome":{"measure":"Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Ertugliflozin 5 mg","deltaMin":-1,"sd":null},{"arm":"Ertugliflozin 15 mg","deltaMin":-0.89,"sd":null},{"arm":"Placebo","deltaMin":-0.2,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":27},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["36763328","34288547","34213819","30830724"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":170},"commonTop":["Hyperuricaemia","Nasopharyngitis","Upper respiratory tract infection","Hypoglycaemia"]}}